home / stock / mxct / mxct news

MXCT News and Press, MaxCyte Inc. From 08/09/23

Stock Information
Company Name: MaxCyte Inc.
Stock Symbol: MXCT
Market: NASDAQ
Website: maxcyte.com
Menu
MXCT MXCT Quote MXCT Short MXCT News MXCT Articles MXCT Message Board
Get MXCT Alerts

News, Short Squeeze, Breakout and More Instantly...
MXCT - MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, developmen...
MXCT - MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

ROCKVILLE, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to suppo...

MXCT - MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

ROCKVILLE, Md., July 13, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovati...

MXCT - MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeu...
MXCT - Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

MXCT - MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Lyell Immunopharma to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors. ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engin...

MXCT - SFIX, BAND and STRL are among after hour movers

2023-06-12 17:14:04 ET Gainers: ARS Pharmaceuticals ( NASDAQ: SPRY ) +5% . Mersana Therapeutics ( MRSN ) +4% . Frontier Group  ( ULCC ) +2% . Sterling Infrastructure ( STRL ) +2% . Stitch Fix ( SFIX ) +2% . Losers:...
MXCT - PRTS, CRBU and NDLS are among after hour movers

2023-06-09 17:15:14 ET Gainers: PepGen  ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital  ( APLD ) +3% . Losers: Couchbase ( BASE ...

MXCT - MaxCyte: Engineering The Next Biotech Wave

2023-05-30 13:38:58 ET Summary Cutting-edge cellular engineering firm MaxCyte (MXCT) has developed a platform which enables modifications to cells. Applications of MaxCyte's cellular engineering platform are far-reaching, such as cell-based therapies, gene editing, and drug discov...

MXCT - MaxCyte, Inc. (MXCT) Q1 2023 Earnings Call Transcript

2023-05-12 13:39:06 ET MaxCyte, Inc. (MXCT) Q1 2023 Earnings Conference Call May 10, 2023 04:30 PM ET Company Participants Sean Menarguez - Head-Investor Relations Doug Doerfler - President & Chief Executive Officer Douglas Swirsky - Chief Financial Office ...
Previous 10 Next 10